Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice

Conditions

Coronary Artery Disease, Percutaneous Transluminal Coronary Angioplasty

Keywords

coronary disease, drug eluting stent

Brief summary

The objective of this study is to evaluate effectiveness and safety of the new drug-eluting stent (DES), as compared with the first-,second-,third-, and fourth-generation DES, in the "real world" daily practice.

Detailed description

Consecutive patients receiving New DES without a mixture of other DES

Kim TO, Kang DY, Ahn JM, Kim MJ, Lee PH, Kim H, Choi Y, Lee J, Lee JM, Jo HH, Park YS, Lim SM, Park SJ, Park DW.

2024-01-014 citations

10.1016/j.jcin.2023.10.068

Comparison of Contemporary Drug-Eluting Stents in Patients Undergoing Complex High-Risk Indicated Procedures

Yeong Jin Jeong, Junho Hyun, Junghoon Lee, Ju Hyeon Kim, Yujin Yang et al. (14 authors)

JACC Asia2022-03-016 citations

10.1016/j.jacasi.2021.10.008

Effectiveness and Safety of Contemporary Drug-Eluting Stents in Patients With Diabetes Mellitus.

Yang Y, Hyun J, Lee J, Kim JH, Lee JB, Kang DY, Lee PH, Ahn JM, Park DW, Park SJ, IRIS-DES Registry Investigators.

2021-09-218 citations

10.1016/j.jacasi.2021.07.009

Optimal Stenting Technique for Complex Coronary Lesions: Intracoronary Imaging-Guided Pre-Dilation, Stent Sizing, and Post-Dilation.

Park H, Ahn JM, Kang DY, Lee JB, Park S, Ko E, Cho SC, Lee PH, Park DW, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park SJ.

2020-05-2735 citations

10.1016/j.jcin.2020.03.023

Prevalence, predictors, prognostic significance, and effect of techniques on outcomes of coronary lesion calcification following implantation of drug-eluting stents: a patient-level pooled analysis of stent-specific, multicenter, prospective IRIS-DES registries

Cheol Hyun Lee, Jung‐Min Ahn, Kyu Sup Lee, Do‐Yoon Kang, Pil Hyung Lee et al. (10 authors)

Coronary Artery Disease2020-04-164 citations

10.1097/mca.0000000000000896

Differential cutoff points and clinical impact of stent parameters of various drug-eluting stents for predicting major adverse clinical events: An individual patient data pooled analysis of seven stent-specific registries and 17,068 patients.

Lee CH, Kang DY, Han M, Hur SH, Rha SW, Her SH, Seung KB, Kim KS, Lee PH, Ahn JM, Lee SW, Park SW, Park DW, Park SJ, IRIS-DES Registry Investigators.

2019-02-0212 citations

10.1016/j.ijcard.2019.01.108

Safety and Effectiveness of Second-Generation Drug-Eluting Stents in Patients With Left Main Coronary Artery Disease.

Lee PH, Kwon O, Ahn JM, Lee CH, Kang DY, Lee JB, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park DW, Park SJ.

2018-02-0122 citations

10.1016/j.jacc.2017.12.032

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* coronary disease amenable to percutaneous coronary intervention (PCI) * no clinical and lesion limitations

Exclusion criteria

* patients with a mixture of several DES * terminal illness with life expectancy less than 1 year * patients with cardiogenic shock

Design outcomes

Primary

Measure	Time frame
Composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR)	at 12 months post procedure

Secondary

Measure	Time frame
Death (all-cause and cardiac)	at 12 months and annually up to 5 years
Myocardial infarction	at 12 months and annually up to 5 years
Stent thrombosis	at 12 months and annually up to 5 years
Target-lesion and target-vessel revascularization	at 12 months and annually up to 5 years
Stroke	at 12 months and annually up to 5 years
Procedural success	at 1 day

Countries

South Korea

Contacts

CONTACTSeung-Jung Park, MD

sjpark@amc.seoul.kr

CONTACTDuk-Woo Park, MD

dwpark@amc.seoul.kr

STUDY_CHAIRSeung-Jung Park, MD

Asan Medical Center

Outcome results